News

The deal will see development of new treatments using Omnis’ cancer-killing virus technology and later sell them if they seem to be successful. In the project, key agents

As part of the deal, Adimab will build a new custom library and transfer it to GSK for its internal use in the discovery of bispecifics. The new

The collaboration will further advance FMI’s position in molecular information and genomic analysis while providing Roche an opportunity to optimize the identification and development of new treatment options

Established in 2012, Melanovus obtained an exclusive global license from the Penn State Research Foundation to a library of compounds and related intellectual property. These compounds originate from

Currently, the company is screening patients for a Phase II trial of the oral formulation of SCY-078 and expects to enroll the first patient in the first quarter

"Sparsentan has the potential to be a significant medicine, and could transform the treatment of FSGS," said John Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals. "The

This new agreement includes a cross-license of intellectual property (IP) on four disease targets, providing each company with exclusive RNA therapeutic license rights for two programs. The agreement

The collaboration, which is being facilitated by Johnson & Johnson Innovation, Boston, focuses on the discovery and development of candidate molecules for the treatment of inflammatory diseases. Under

Under this agreement, Fast Forward will provide funding to Bionure for the late-preclinical development of BN201 to enable IND filling to support the Phase 1 clinical study in